Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of imatinib for severe pulmonary arterial hypertension
2010-021960-14Phase 3Terminated
- Sponsor
- Novartis
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of imatinib in pulmonary arterial hypertension (PAH), sponsored by Novartis. Primary endpoints: Long-term safety and tolerability and Change in six-minute walk distance. Started Mar 2011; status: terminated.
02
Drugs
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2010-021960-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021960-14.